

**Date: February 08, 2024**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited (NSE),</b> Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051. <b>Scrip Code-LINCOLN</b>	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001. <b>Scrip Code-531633</b>
---	--

Dear Sir / Madam,

**Subject: Disclosure under Reg.30 of SEBI LODR for Advisory letter received from National Stock Exchange of India Ltd (“NSE”).**

**Ref: NSE letter NSE/LIST/C/2024/0032 dated January 08, 2024.**

In pursuant to the Regulation 30 of SEBI LODR, we would like to inform you that the Company Secretary informed the Board regarding filling of the revised shareholding patterns as advised by the NSE and the same has been taken on records by NSE. The Board taken note of the Advisory letter of the NSE dated January 08, 2024 and instructed the CS to adhere and take abundant precaution in future, provide adequate and accurate disclosures in the submissions pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to kindly take note of the same.

Thanking you,

Yours faithfully,

**For Lincoln Pharmaceuticals Ltd**

---

**Trusha Shah**  
**Company Secretary & Compliance Officer**

**Regd. Office :** "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.

**Phone :** +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288

**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India

**Phone :** +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com

